Excel Diagnostics

Ebrahim S Delpassand, M.D.

Founder/Chairman/Medical Director: Excel Diagnostics & Nuclear Oncology Center Houston, TX

Dr. Ebrahim Delpassand is the Chairman and Medical Director of Excel Diagnostics and Nuclear Oncology Center. He holds an academic position as Clinical Professor in Radiation Oncology, at the University of Texas, Medical Branch. He completed his residency training in Nuclear Medicine, and Anatomical and Clinical Pathology at Baylor College of Medicine in Houston in 1991. He is Board certified in Nuclear Medicine and Fellow of the American College of Nuclear Medicine.

Dr. Delpassand is the former deputy chairman, associate professor, and chief of clinical nuclear medicine at M.D. Anderson Cancer Center in Houston, Texas. His prestigious credentials and extensive experience include the disciplines of therapeutic nuclear medicine, Peptide Receptor Radionuclide Therapy (PRRT), nuclear cardiology, monoclonal antibody imaging, and positron emission tomography (PET). Dr. Delpassand is the principle Investigator of multiple Investigational New Drug (IND) applications in the areas of diagnostic and Therapeutic Nuclear Medicine authorized by U.S. Food and Drug Administration (FDA).

 

Mohammadali Hamiditabar, M.D.

Research Director,
Senior Clinical Research Associates

A graduate from Tabriz Azad University in 1995, Dr. Hamidi is an ECFMG/ USMLE certified physician. After more than 17 years of clinical experience he joined Excel Diagnostics and Nuclear Oncology Center in April of 2012. As an acting associate with Excel Diagnostic’s Medical Director, Ebrahim Delpassand, MD, Dr. Hamidi served as the Project Manager and Senior Clinical Research Associates for phase 1, 2 and 3 (including pivotal) trials on targeted Peptide Receptor Radionuclide Therapy (PRRT) for neuroendocrine cancers. Dr. Hamidi is an active participant in the development of clinical trial protocols and supports IND filing for novel oncology radiodiagnostic and radionuclide drugs. He is the primary contact to the major health authorities (FDA), ethic committees (IRB), and clinical research organizations (CROs). He has extensive experience in all operational aspects of clinical trials including data collection, study site management, design and handling of Adverse Events (AE) and Serious AE (SAE) reports, and supervises and manages team members in preparation of clinical trials. He has also been involved in overseeing and managing patients receiving PRRT under different IND projects.
Since April 2016, Dr. Hamidi has served as the Director of Research for Excel Diagnostics .He is leading the research team with high emphasis on education and training in the regulatory and compliance issues related to human research and excellence in conducting clinical research, data collection and analysis.

 

Gelareh Vahdati, M.D.

Senior Clinical Research Associate,

Dr. Gelareh Vahdati graduated from Tehran Azad Medical School in Iran. Later on, she worked as a research scientist and physician in Azad University hospitals in Iran, in addition to working as a general practitioner for her private practice. Her research was mostly focused in the field of Rheumatology, Oncology and Nuclear Medicine. Her previous experiences and ardent interest in the field of nuclear medicine led her to work under the mentorship of Dr. Ebrahim Delpassand in Excel Diagnostics and Nuclear Oncology Center as a Clinical Research Associate (CRA). She has extensive experience in dealing with regulatory authorities like FDA and other ethics and oversight committees. She has conducted several phase 1, 2 and 3 clinical trials including 68Ga-DOTATATE PET/CT scan for diagnosis and staging of neuroendocrine tumors, 177Lu PRRT in somatostatin receptor expressing NETs, 68Ga-PSMA PET/CT scan for diagnosis and management of prostate cancer, Aminomedix® (amino acids infusion) for kidney radio-protection during PRRT, 99mTc -Etarfolatide SPECT/CT scan in advanced folate receptor expressing solid tumors, 68Ga -EC2115 radiolabeled folate receptor imaging agent and TKM-080301 therapy (TEKMIRA Pharmaceuticals), in collaboration with Westchase Clinical Oncology Center, in patients with advanced solid tumors. She plays an active role mobilizing the research department team and its activities.